Dixon EL, et al. - This paper gauged the efficacy and safety of travoprost in pediatric patients with ocular hypertension or glaucoma. It also entailed the illustration of its noninferiority to timolol. Travoprost appeared to be noninferior to timolol in lowering intraocular pressure (IOP) in the study cohort. It was reported that travoprost was well-tolerated, and there were no treatment-related systemic adverse events.